>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
miR-182在子宫内膜癌中表达及其对子宫内膜癌细胞增殖和凋亡的影响
作者:姚红梅  孔凡荣  周烨 
单位:济宁医学院附属医院 妇产科, 山东 济宁 272100
关键词:子宫内膜癌 miR-182 增殖 凋亡 
分类号:R737.33
出版年·卷·期(页码):2018·37·第四期(653-659)
摘要:

目的:检测miR-182在子宫内膜癌组织中的表达,探讨其对子宫内膜癌细胞增殖、凋亡的影响及其机制。方法:用real-time PCR检测子宫内膜正常组织和癌组织中miR-182的表达;体外使用miR-182抑制剂和(或)si-Foxo1转染子宫内膜癌细胞RL95-2,用MTT和Annexin V-FITC/PI双染法及Western blot分别检测细胞增殖和凋亡水平以及Cyclin D1、caspase3和肿瘤抑制基因Foxo1的表达。结果:miR-182在子宫内膜癌组织中的表达较正常组织显著升高(P<0.05);下调miR-182可抑制RL95-2细胞的增殖活性,增加细胞凋亡百分比,同时可促使Cyclin D1、active caspase3和Foxo1的表达增加。抑制Foxo1可部分逆转miR-182抑制剂的作用。结论:miR-182在子宫内膜癌中表达异常增高;miR-182异常表达可通过抑制Foxo1表达促使RL95-2细胞的增殖,并抑制其凋亡。

Objective:To detect the expression of miR-182 in endometrial carcinoma tissues and investigate the effects and mechanisms of miR-182 on the proliferation and apoptosis of endometrial carcinoma cells. Methods:The expression of miR-182 was detected in endometrial carcinoma tissues and normal endometrial tissues by real-time PCR. Endometrial cancer cells RL95-2 were transfected with miR-182 inhibitor and/or si-Foxo1 in vitro. Then the proliferative activity and apoptotic percentage of cells were measured by MTT assay and Annexin V-FITC/PI double staining assay; the expression of Cyclin D1 and Foxo1 were detected by Western blot. Results:Compared with normal endometrial tissues, the expression of miR-182 in endometrial carcinoma was significantly increased (P<0.05). Downregulation of miR-182 could significantly inhibit cell proliferation, increase the percentage of apoptosis and promote the expression of Foxo1, Cyclin D1 and active caspase3. But the inhibition of Foxo1 expression could partially reverse these effects of miR-182 inhibitor. Conclusion:miR-182 was abnormally high expressed in endometrial carcinoma, and its abnormal expression could promote cell proliferation and inhibit apoptosis of RL95-2 cells by inhibiting Foxo1 expression.

参考文献:

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J].CA Cancer J Clin, 2017, 67(1):7-30.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2):115-132.
[3] 夏玲芳, 吴小华. 子宫内膜癌的手术治疗[J].中国实用妇科与产科杂志, 2017, 33(5):461-465.
[4] GERETTO M, PULLIERO A, ROSANO C, et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators[J].Am J Cancer Res, 2017, 7(6):1350-1371.
[5] SPITSCHAK A, MEIER C, KOWTHARAPU B, et al. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-kappaB to loss of the HES1/Notch1 regulatory circuit[J].Mol Cancer, 2017, 16(1):24-39.
[6] CHIANG C H, CHU P Y, HOU M F, et al. MiR-182 promotes proliferation and invasion and elevates the HIF-1alpha-VEGF-A axis in breast cancer cells by targeting FBXW7[J].Am J Cancer Res, 2016, 6(8):1785-1798.
[7] 安琪, 马晓欣. miRNA-302 c在子宫内膜癌组织中的表达及其与临床病理资料的关系[J].现代肿瘤医学, 2017, 25(1):127-130.
[8] 常香荣, 刘蓓蕾, 张海云. miR-520通过靶向调节BAMBI抑制肝星状细胞增殖的研究[J].现代医学, 2016, 44(11):1615-1620.
[9] 张姣, 宗毅, 沙晓峰, 等. Hsa-miR-29c在食管鳞状细胞癌中的表达及其临床意义[J].现代医学, 2014, 42(9):971-975.
[10] MYATT S S, WANG J, MONTEIRO L J, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer[J].Cancer Res, 2010, 70(1):367-377.
[11] QIN W, REN Q, LIU T, et al. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1[J].FEBS Lett, 2013, 587(9):1434-1439.
[12] NING T, ZHANG H, WANG X, et al. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer[J].Tumour Biol, 2017, 39(6):1-13.
[13] LI Y, CHEN S, SHAN Z, et al. miR-182-5p improves the viability, mitosis, migration, and invasion ability of human gastric cancer cells by down-regulating RAB27A[J].Biosci Rep, 2017, 37(3):1-21.
[14] LIU Y, ZHANG B, SHI T, et al. miR-182 promotes tumor growth and increases chemoresistance of human anaplastic thyroid cancer by targeting tripartite motif 8[J].Onco Targets Ther, 2017, 10(2017):1115-1122.
[15] FASIHI-RAMANDI M, MORIDNIA A, NAJAFI A, et al. Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression[J].Biomed Pharmacother, 2017, 89(2017):1152-1158.
[16] LIU H, WANG Y, LI X, et al. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1[J].Tumour Biol, 2013, 34(3):1713-1722.
[17] LIU Z, LIU J, SEGURA M F, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma[J].J Pathol, 2012, 228(2):204-215.
[18] HUANG Y, FAN X X, TAO R, et al. Effect of miR-182 on hepatic fibrosis induced by schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway[J].J Cell Physiol, 2018, 2018(1):1-35.
[19] KIM K M, PARK S J, JUNG S H, et al. miR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting foxol[J].J Bone Miner Res, 2012, 27(8):1669-1679.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 250585 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364